Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: A cost-utility analysis

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 567-574

  Joerger, M ^a   Matter Walstra, K ^b   Fruh M ^a   Kuhnel U ^c   Szucs, T ^b   Pestalozzi, B ^d   Schwenkglenks, M ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cetuximab; Chemoimmunotherapy; Cost effectiveness; Non small cell lung cancer; Qualy

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NAVELBINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INTERMITTENT THERAPY; HUMAN; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY ADJUSTED LIFE YEAR; SWITZERLAND;

EID: 79952026498     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq431     Document Type: Article

References (35)

1. William WN Jr, Lin HY, Lee JJ et al. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009; 136: 701-709.
2. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008; 19: 99-113.
3. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
4. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
6. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
7. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
8. Mahaffey CM, Davies AM, Lara PN Jr et al. Schedule-dependent apoptosis in Kras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007; 8: 548-553.
9. Riely GJ, Rizvi NA, Kris MG et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 264-270.
10. Dedes KJ, Matter-Walstra KW, Schwenkglenks M et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45(8): 1397-1406.
11. Hirth RA, Chernew ME, Miller E et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
12. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 2004; 7: 70-78.
13. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009; 12: 20-27.
14. D'Addario G, Rauch D, Stupp R et al. Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008; 19: 739-745.
15. Schweizerisches Arztneimittelkompedium. www.documed.ch (last accessed in August 2010).
16. Swiss National Tariff Catalogue. www.tarmed.ch (last accessed in August 2010).
17. Bundesamt für Gesundheit Analyseliste. http://www.bag.admin.ch/themen/krankenversicherung/index.html?lang=de (last accessed in August 2010).
18. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007; 12: 478-483.
19. Mayordomo JI, Lopez A, Vinolas N et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25: 2533-2542.
20. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
21. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: a metaanalysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
22. Neubauer MA, Hoverman JR, Kolodziej M et al. Cost effectiveness of evidencebased treatment guidelines for the treatment of non-small-cell lung cancer in the communitysetting. J Oncol Pract 2010; 6: 12-18.
23. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008; 68: 1105-1113.
24. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
25. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048.
26. Pompen M, Novak A, Gok M. Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care in NSCLC (abstract no. PD6-3-5). J Thorac Oncol 2007 Aug; 2 (8 Suppl 4): S433.
27. CôtéI, Leighl NB, Gyldmark M et al. Pharmacoeconomic analyses of erlotinib compared with best supportive care for the treatment of relapsed non-small cell lung cancer from the Canadian public health care perspective (abstract no PCN11). Value Health 2006 Nov-Dec; 9(6): A279.
28. Annemans L, Van Cutsem E, Humblet Y et al. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan-a Belgian analysis. Acta Clin Belg 2007; 62: 419-425.
29. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007; 96: 206-212.
30. Raftery J. Review of NICE's recommendations, 1999-2005. BMJ 2006; 332: 1266-1268.
31. Brown B, Diamantopoulos A, Bernier J et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008; 11: 791-799.
32. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-1552.
33. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
34. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-1641.
35. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007; 18: 1481-1491.